Anaesthetic management of patients being treated with anticoagulants

Current Opinion in Anaesthesiology

Volumn 10, Issue 3, 1997, Pages 234-239

  Bullingham, Alan ^a   Priestley, Mark ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANESTHESIA; ANTICOAGULANT THERAPY; DRUG MONITORING; EPIDURAL ANESTHESIA; HUMAN; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; SPINAL ANESTHESIA; VEIN THROMBOSIS;

EID: 0030839335     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199706000-00016     Document Type: Review

References (45)

1. Bryan AJ, Butchart EG: Prosthetic heart valves and anticoagulant management during non-cardiac surgery. Br J Surgery 1995, 82:577-578. A discussion of the limitations of current guidelines for patients with prosthetic heart valves having noncardiac surgery.
2. Souto JC, Oliver A, Zauzu-Jausoro I, Vives A, Fontcuberta J: Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant. J Oral Maxillofacial Surg 1996, 54:27-32.
3. Otley CC, Fewkes JL, Frank W, Olbricht SM: Complications of cutaneous surgery in patients who are taking warfarin, aspirin or nonsteroidal anti-inflammatory drugs. Arch Dermatol 1996, 132:161-166.
4. Kingston TE, Nonnenmacher AK, Crowe H, Costello AJ, Street A: Further evaluation of transurethral laser ablation of the prostate in patients treated with anticoagulant therapy Aust NZ J Surg 1995, 65:40-43.
5. White RH, McKittrick T, Hutchinson R, Twitchell J: Temporary discontinuation of warfarin therapy: changes in the international normalised ratio. Ann Int Med 1995, 122:40-42.
6. Bullingham A, Strunin L: Prevention of postoperative venous thromboembolism. Br J Anaesth 1995, 75:622-630. A comprehensive review of aspects of prevention of venous thromboembolism relevant to anaesthetists. The paper includes a discussion of regional anaesthesia in patients on anticoagulant prophylaxis.
7. Bounameaux H, Goldhaber SZ: Uses of low molecular-weight heparin. Haemostasis 1995, 9:213-219.
8. Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Schmidt R, Tejwani S, Stanley JC: Effective and less toxic reversal of low molecular weight heparin anticoagulation by a designer variant of protamine. J Vasc Surg 1995, 21:839-845.
9. Kearon C, Hirsh J: Starting prophylaxis for venous thromboembolism postoperatively. Arch Int Med 1995, 155:366-372.
10. Weale AE, Warwick DJ, Durant N, Prothero D: Is there a clinical interaction between low molecular weight heparin and nonsteroidal analgesics after total hip replacement. Ann Roy Coll Surg Engl 1995, 77:35-37.
11. Pryle BJ, Carter JA, Cadoux-Hudson T: Spinal subdural haematoma following dural puncture with a 25G pencil point needle at T12-L1 in a patient taking aspirin. Anaesthesia 1996, 51:263-265.
12. Hynson JM, Katz A, Bueff HU: Epidural hematoma associated with Enoxaparin. Anesth Analg 1996, 82:1072-1075.
13. Sternlo J-E, Hybbinette CH: Spinal subdural bleeding after attempted epidural and subsequent spinal anaesthesia in a patient on thromboprophylaxis with low molecular weight heparin. Acta Anaesth Scand 1995,39:557-559.
14. Vandepol C: Enoxaparin and epidural analgesia [Letter]. Anesthesiology 1996, 85:433-443.
15. Rabito SF, Ahmed S, Feinstein L, Winnie AP: Intrathecal bleeding after intraoperative use of heparin and urokinase during continuous spinal anaesthesia. Anesth Analg 1996, 82:409-411.
16. Bougher RJ, Ramage D: Spinal subdural haemotoma following combined spinal-epidural anaesthesia. Anaeth Intens Care 1995, 23:111-113
17. Weitz SR, Chan V: Enoxaparin and analgesia [Letter]. Anesthesiology 1996, 85:432-433.
18. Wildsmith JAW, Maclure JH: Anticoagulant drugs and the central nerve blockade. Anaesthesia 1991, 46:613-614.
19. Stafford Smith M: Impaired haemostasis and regional anaesthesia. Can J Anaesth 1996, 43:129-135. A review discussing the pathophysiology and incidence of spinal haematoma associated with spinal or epidural procedures in the presence of impaired haemostasis. Strategies to avoid causing a spinal haematoma are discussed including technical aspects of performing spinal or epidural blockade and management of anticoagulant deep venous thrombosis prophylaxis.
20. Vandermeulen EP, Van Aken H, Vermylen J: Anticoagulants and spinal-epidural anaesthesia. Anesth Analg 1994, 79:1165-1177
21. Horlocker TT, Wedel DJ, Schroeder DR, Rose SH, Elliott BA, McGregor DG, Wong GY: Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anesth Analg 1995, 80:303-309.
22. Webb AR, Mythen MG, Jacobson D, Mackie IJ: Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Intens Care Med 1995, 21:84-93. A very readable and useful summary of coagulation management for both CPB circuits and other extracorporeal circuits likely to be encountered in the intensive care unit.
23. Bull BS, Huse WM, Blauer FS, Korpman RA: Heparin therapy during extracorporeal circulation, II: the use of a dose-response curve to individualise heparin and protamine dosages. J Thorac Cardiovasc Surg 1975, 69:685-689.
24. Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough MD, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG: The impact of heparin concentration and ACT monitoring on blood conservation. J Thorac Cardiovasc Surg 1995, 110:46-54.
25. Øvrum E, Brosstad F, Holen EA, Tangen G, Abdelnoor M: Effects on coagulation and fibrinolysis with reduced versus full systemic heparinisation and heparin-coated cardiopulmonary bypass. Circulation 1995, 92:2579-2584.
26. Øvrum E, Holen EA, Tangen G, Brosstad F, Abdelnoor M, Ringdal ML, Oystese R, Istad R: Completely heparinised cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995, 60:365-371.
27. Delaria GA, Tyner JJ, Hayes CL, Armstrong BW: Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994, 129:945-951.
28. Wilhelm MJ, Schmid C, Kececioglu D, Möllhoff T, Ostermann H, Scheld HH: Cardiopulmonary bypass in patients with heparin-induced thrombocytopaenia using Org 10172. Ann Thorac Surg 1996, 61:920-924.
29. Brisler SJ, Ofosu FA, Heigenhauser GJF, Gianese F, Buchanan MR: Is heparin the ideal anticoagulant for Cardiopulmonary bypass? Dermatan sulphate may be an alternative choice. Throm Haem 1994, 71:468-473.
30. Reiss F-C, Lower C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, Pötzsch B: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995, 110:265-267.
31. Corbeau JJ, Jacob JP, Moreau X, Coltineau C, De-Brux JL, Delhumeau A: lloprost (llomedine) and extracorporeal circulation with conventional heparinisation in a patient with heparin-induced thrombocytopaenia. Ann Fr Anesth Reanim 1993, 12:55-59.
32. Levy LH, Cormack JG, Morales A: Heparin neutralisation by recombinant platelet factor 4 and protamine. Anesth Analg 1995, 81:35-37.
33. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM: Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 1995, 91:2188-2194.
34. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995, 108(suppl 1):258s-275s. An excellent review of the pharmacology and clinical use of heparin (unfractionated and LMWH).
35. Despotis GJ, Alsoufiev A, Spitzagel E, Goodnough LT, Lappas DG: Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses. Ann Thorac Surg 1996, 61:795-799.
36. Wang J-S, Lin C-Y, Karp RB: Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg 1994, 79:9-13.
37. Huyzen RJ, van Oeveren W, Wei F, Stettingwerf P, Boonstra PW, Gu YJ: In vitro effect of haemodilution on activated clotting time and high dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg 1996, 62:533-537.
38. Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E: Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 1996, 82:1126-1131.
39. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA: Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open heart surgery. Anesthesiology 1995, 83:679-689.
40. McLaren ID, Crider BA: Monitoring the coagulation system. Anesth Clin N Am 1994, 12:211-236.
41. Breddin HK, Radziwon P, Boczkowska-Radziwon B: Laboratory monitoring of new antithrombotic drugs. Clin Lab Med 1994, 14:825-845.
42. Callas D, Fareed J: Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haem 1995, 74:473-481. A review of the pharmacology of a group of drugs that act at different sites of thrombin generation including hirudin and several other new agents.
43. Michelson AD: Flow cytometry: a clinical test of platelet function. Blood 1996, 87:4925-4936.
44. Thromboelastography. Semin Thromb Hem 1995, 21(suppl 4) An issue devoted to all aspects of thromboelastography with particularly good sections on the description and explanation of the technique and on its uses in cardiac anaesthesia.
45. Mallett SV, Cox DJA: Thromboelastography. Br J Anaesth 1992,69:307-313.